Patents Examined by Christopher James Nichols
-
Patent number: 6835565Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays.Type: GrantFiled: September 17, 2001Date of Patent: December 28, 2004Assignee: Pharmacia & Upjohn CompanyInventors: Mark E. Gurney, Michael Jerome Bienkowski, Robert Leroy Heinrikson, Luis A. Parodi, Riqiang Yan
-
Patent number: 6835711Abstract: Methods and compositions are provided for preventing or inhibiting neuronal degeneration, or for promoting nerve regeneration, in the central nervous system (CNS) or peripheral nervous system (PNS), or for protecting CNS cells from glutamate toxicity, comprising an effective amount of an agent selected from the group consisting of (a) poly-Glu,Tyr and (b) T cells which have been activated by poly-Glue,Tyr.Type: GrantFiled: June 28, 2001Date of Patent: December 28, 2004Assignee: Yeda Research and Development Co. Ltd.Inventors: Michal Eisenbach-Schwartz, Ester Yoles, Ehud Hauben
-
Patent number: 6828124Abstract: A family of somatotropin vectors with which micro-organisms, preferably bacteria such as, but not limited to E. coli, can be transformed to enable the expression of bovine somatotropin at high levels using conventional fermentation and induction conditions.Type: GrantFiled: June 17, 2002Date of Patent: December 7, 2004Assignee: Monsanto Technology LLCInventors: Gregg Bogosian, Julia P. O'Neil, Noelle D. Aardema
-
Patent number: 6821946Abstract: The invention provides a method of treating nerve damage involving administering to the damaged nerve an effective non-toxic amount of an MGF (mechano-growth factor) Insulin-like Growth Factor I (IGF-I) isoform which includes amino acid sequences encoded by nucleic acid sequences of IGF-I exons 4, 5 and 6 in the reading frame of MGF and having the ability to reduce motoneurone loss by 20% or greater in response to nerve avulsion.Type: GrantFiled: May 10, 2001Date of Patent: November 23, 2004Assignees: University College London, East Grinstead Medical Research TrustInventors: Geoffrey Goldspink, Giorgio Terenghi
-
Patent number: 6821743Abstract: DNA encoding an endothelin receptor shown in SEQ ID NO: 1 or 2 in the Sequence Listing is isolated from cDNA which is prepared from poly(A)+RNA derived from a human placenta. In addition, an expression vector containing the DNA and a transformant containing the expression vector are obtained. An endothelin receptor is obtained by culturing this transformant. A receptor shown in SEQ ID NO: 1 is an ETA-receptor which has a high affinity for endothelins 1 and 2, especially for the endothelin 1. A receptor shown in SEQ ID NO: 2 is an ETB-receptor which has an affinity for endothelins 1, 2 and 3 with no selectivity.Type: GrantFiled: August 16, 2001Date of Patent: November 23, 2004Assignee: Shionogi Sieyaku Kabushiki KaishaInventors: Hiroo Imura, Kazuwa Nakao, Shigetada Nakanishi
-
Patent number: 6821750Abstract: The present invention provides nucleic acids encoding a novel ABC family cholesterol transporter, ABCG8. The herein-disclosed sequences can be used for any of a number of purposes, including for the diagnosis and treatment of cholesterol-associated disorders, including sitosterolemia, and for the identification of molecules that associate with and/or modulate the activity of ABCG8.Type: GrantFiled: November 20, 2001Date of Patent: November 23, 2004Assignees: Tularik Inc., Board of Regents, The University of Texas SystemInventors: Helen H. Hobbs, Bei Shan, Robert Barnes, Hui Tian
-
Patent number: 6806053Abstract: Assays for detecting the presence and activity of cell-signaling components. These assays include luminescence polarization assays for detecting cell-signaling nucleotides and modulators of receptors and enzymes related to the generation and activity of such nucleotides.Type: GrantFiled: January 23, 2001Date of Patent: October 19, 2004Assignee: LJL BioSystems, Inc.Inventors: J. Richard Sportsman, Lawrence M. Kauvar
-
Patent number: 6803233Abstract: The present invention provides a model for studying the development of, and/or pathologies associated with neurodegenerative diseases, and agents that can alter such development and/or pathologies. The model of the invention is especially useful as an Alzheimer's disease model. The model of the invention provides brain cells and a method for increasing neurodegenerative disease characteristics in such cells, especially, induction of neurofibrillary tangles and/or phosphorylated tau and/or tau fragments and/or the production and/or release of cytokines and/or microglia reactions and/or activations and/or inflammation and/or conversion of p35 to p25 and/or the levels and activities of protein kinases by selectively increasing the concentration of cathepsin D to an effective level, and/or by lowering the concentration of cholesterol in such cells.Type: GrantFiled: July 31, 2001Date of Patent: October 12, 2004Assignee: The Regents of the University of CaliforniaInventors: Gary Lynch, Xiaoning Bi
-
Patent number: 6797264Abstract: Use of a substance that upon administration will lead to increased concentrations of growth hormone, such as growth hormone, a functionally equivalent analogue thereof or a substance that will increase the release of endogenous growth hormone, for the production of a medicinal product for treatment of abnormal conditions affecting neural stem cells, progenitor cells and/or cells derived from neural stem cells or progenitor cells, especially conditions affecting the oligodendroglia, astroglia, and/or neuronal cells. In vitro and in vivo methods for inducing lineage determination, propagating and/or inducing or maintaining the genesis of neurons, oligodendrocytes, astroglial cells from progenitor cells, stem cells and/or cells derived from said cells by administrating to the cells a substance that increases the concentration of growth hormone.Type: GrantFiled: July 13, 2001Date of Patent: September 28, 2004Assignee: Cellartis ABInventor: Peter Eriksson
-
Patent number: 6790610Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.Type: GrantFiled: June 27, 2001Date of Patent: September 14, 2004Assignee: Pharmacia & Upjohn CompanyInventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
-
Patent number: 6787519Abstract: The present invention provides methods inhibiting formation of neurofibrillary tangles; and methods for treating disorders relating to apolipoprotein E (apoE) in a subject. The methods generally involve reducing the level of a carboxyl-terminal truncated form of apoE in a neuronal cell of a subject. The invention further provides isolated cells comprising a nucleic acid molecule encoding a carboxyl-terminal truncated form of apoE; and methods of screening compounds using the cells. The invention further provides compounds that inhibit an apoE cleavage enzyme, and that reduce the formation of neurofibrillary tangles in a neuronal cell. The invention further provides transgenic non-human animals that include as a transgene a nucleic acid that encodes a carboxyl-terminal truncated form of apoE; as well as methods of screening compounds using transgenic animals.Type: GrantFiled: November 2, 2001Date of Patent: September 7, 2004Assignee: The Regents of the University of CaliforniaInventors: Yadong Huang, Robert W. Mahley
-
Patent number: 6787319Abstract: Novel proteins which bind human &bgr;-amyloid peptide, polynucleotides which encode these proteins, and methods for producing these proteins are provided. Diagnostic, therapeutic, and screening methods employing the polynucleotides and polypeptides of the present invention are also provided. Transgenic animals and knockout animals are also provided.Type: GrantFiled: May 9, 2001Date of Patent: September 7, 2004Assignee: American Home Products Corp.Inventors: Bradley A. Ozenberger, Jonathan A. Bard, Eileen M. Kajkowski, Jack S. Jacobsen, Stephen G. Walker, Heidi Sofia, David Howland
-
Patent number: 6787637Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A&bgr; in the brain of a patient Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred including N-terminal fragments of A&bgr; and antibodies binding to the same.Type: GrantFiled: November 28, 2000Date of Patent: September 7, 2004Assignee: Neuralab LimitedInventor: Dale B. Schenk
-
Patent number: 6780641Abstract: An immortalized human cell line is provided which has the characteristics of human embryonic microglia. Such immortalized microglia cells express CD68, CD11c and MHC class I and II antigens as surface markers; have demonstrable phagocytic properties; and produce progeny continuously while maintained in culture. A method of transforming human microglial cells into an immortalized cell line is also provided. The genetically modified human microglia cells can express active substances from a selected group consisting of MIP-1&bgr;, MCP-1, IL-1&bgr;, IL-6, IL-12, and IL-15; and in the stimulated state can overexpress at lest cytokines, chemokines, and other cytotoxic and neurotoxic substances. Such immortalized microglia cells can be used for screening of compounds for diseases. These cells may be utilized for the treatment of at least Alzheimer disease, Parkinson disease, Huntington disease, amyotrophic lateral sclerosis, stroke, spinal cord injuries, ataxia, autoimmune diseases and AIDS-dementia.Type: GrantFiled: June 22, 2001Date of Patent: August 24, 2004Assignee: University of British ColumbiaInventor: Seung U. Kim
-
Patent number: 6780842Abstract: A neuroprotective composition for protecting neuronal cells against oxidative stress and methods for using and preparing the same. More particularly, the neuroprotective composition of the invention comprises a therapeutically effective amount of ceruloplasmin or a functional derivative thereof. The neuroprotective composition is characterized in that it protects neuronal cells from reactive oxygen species such as •O2− and •OH. In a preferred embodiment, the neuroprotective composition further comprises an antioxidant consisting of catalase or of an amphiphilic physiological antioxidative solution comprising a mixture of pyruvate, antioxidant, and lipid(s) such as fatty acids. The neuroprotective composition could be used for the treatment of brain trauma, brain or cerebrovascular ischemia, neurodegenerative diseases, poisoning of neuronal cells, the diminution of drugs side effects and for preservation of neuronal grafts.Type: GrantFiled: November 5, 2001Date of Patent: August 24, 2004Assignee: Warner-Lambert Company LLCInventors: Joanne Paquin, Mircea-Alexandru Mateescu, Éric De Grandpré
-
Patent number: 6780839Abstract: The invention is based on the finding that the secretin receptor is expressed in tissues present in the distal lung of humans. In patient with CF, levels of the receptor are elevated compared to normal tissue. Treatment of tissue by secretin stimulates the movement of negative ions in the tissue. The invention provides methods of treatment of cystic fibrosis or COPD in a patient by administering to said patient an effective amount of an agent which triggers anion efflux in respiratory tissue via the activation of a secretin receptor.Type: GrantFiled: July 3, 2001Date of Patent: August 24, 2004Assignee: Pharmagene Laboratories Ltd.Inventors: Richard J. Davis, Keith J. Page
-
Patent number: 6767738Abstract: The present invention is directed to methods of repairing damaged or diseased, specialized or differentiated tissue in mature animals, particularly neuronal tissue such as retinas. In particular, the invention relates to transplantation of adult, hippocampus-derived progenitor cells into a selected neural tissue site of a recipient. These cells can functionally integrate into mature and immature neural tissue. The invention encompasses, in one aspect, repopulating a retina of a dystrophic animal with neurons, by injecting clonally derived, adult central nervous system derived stem cells (ACSC) derived from a healthy donor animal into an eye of the dystrophic recipient. Herein disclosed is the first successful and stable integration of clonally derived ACSC into same-species but different strain recipients (e. g., Fischer rat-derived adult hippocampal derived progenitor cells (AHPCs) into dystrophic RCS rats). Surprisingly, AHPCs were also found to integrate successfully into a xenogeneic recipient (e.g.Type: GrantFiled: February 12, 2002Date of Patent: July 27, 2004Assignee: The Salk Institute for Biological StudiesInventors: Fred H. Gage, Theo Palmer, Francis G. Safar, Jun Takahashi, Masayo Takahashi
-
Patent number: 6761888Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A&bgr; in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A&bgr; and antibodies binding to the same.Type: GrantFiled: May 26, 2000Date of Patent: July 13, 2004Assignee: Neuralab LimitedInventor: Dale B. Schenk
-
Patent number: 6759188Abstract: The present invention relates to a method for producing a prophylactically or therapeutically active protein, the syringe being filled with a body fluid and incubated, and the prophylactically or therapeutically active protein subsequently being formed in the body fluid.Type: GrantFiled: December 31, 2002Date of Patent: July 6, 2004Assignee: Orthogen AGInventors: Julio Reinecke, Hans Meijer, Peter Wehling
-
Patent number: 6759386Abstract: Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.Type: GrantFiled: April 6, 2001Date of Patent: July 6, 2004Inventor: Wayne P. Franco